KALA Stock Risk & Deep Value Analysis

KALA BIO Inc

Healthcare • Biotechnology

DVR Score

2.5

out of 10

Risk Trap

The Bottom Line on KALA

We analyzed KALA BIO Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran KALA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Mar 26, 2026•Run Fresh Analysis →

📈KALA Performance Overview3yr weekly

📊

Unlock KALA Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

KALA Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

High

Market Risk

High

About KALA BIO Inc (KALA)

Sector

Healthcare

Industry

Biotechnology

Market Cap Category

small

KALA Deep Value Analysis

KALA BIO Inc. remains a highly speculative, pre-revenue biotech with 10x growth potential contingent on successful clinical trials for XP-898 in rare ocular diseases. The significant 37.5% decline in market capitalization to $0.20B in just 22 days since the last analysis reflects a material deterioration in market confidence regarding its financial outlook or development timeline. While the unmet medical need for XP-898 and potential for premium pricing are attractive, the company faces substantial execution, financial, and regulatory risks. Cash burn and the need for significant further capital for commercialization are paramount concerns, making it an exceptionally high-risk investment despite the underlying market opportunity.

KALA Red Flags & Warning Signs

Premium

⚠
Negative or inconclusive results from XP-898 Phase 2/3 clinical trial
⚠
Failure to secure sufficient additional capital for operations and commercialization
⚠
Increased competition or regulatory hurdles for ocular disease treatments

Unlock KALA Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

KALA Competitive Moat Analysis

Premium

Moat Rating

Narrow

Moat Trend

Stable

Moat Sources

1 Identified

Intangible Assets/IP

The moat's durability for KALA BIO Inc. is solely dependent on the successful clinical development, regulatory approval, and patent protection of its lead candidate XP-898. Failure in any of these areas would immediately erode its competitive advantage.

KALA Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

KALA Catalysts & Growth Drivers

Near-Term (0-6 months)

•Q1 2026 Earnings Report (estimated early-May 2026) focusing on cash runway and operational updates
•Potential announcement of interim Phase 2/3 clinical data for XP-898
•Strategic partnership or non-dilutive financing agreement

Medium-Term (6-18 months)

•Full Phase 2/3 clinical data readout for XP-898 (late 2026/early 2027)
•Potential BLA/NDA submission to regulatory authorities
•Securing additional dilutive/non-dilutive funding for commercialization preparations

Long-Term (18+ months)

•Regulatory approval and commercial launch of XP-898 (2028-2029)
•Expansion of XP-898 into additional rare ocular indications
•Achieving significant market share in target rare ocular disease segments

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

KALA Bull Case: What Could Go Right

✓
Positive Phase 2/3 clinical data for XP-898, particularly interim readouts.
✓
Announcement of a strategic partnership or non-dilutive financing.
✓
Demonstrated extension of cash runway in subsequent earnings reports.

Bull Case Analysis

See what could go right with Premium

🔔

Never miss a move on KALA

Create a free account to set price alerts and get notified on Telegram when KALA hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for KALA BIO Inc (KALA)?

As of March 26, 2026, KALA BIO Inc has a DVR Score of 2.5 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What ticker symbol does KALA BIO Inc use?

KALA is the ticker symbol for KALA BIO Inc. The company trades on the NCM.

What is the risk level for KALA stock?

Our analysis rates KALA BIO Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

How often is the KALA DVR analysis updated?

Our AI-powered analysis of KALA BIO Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 26, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.